⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for ro6870810

Every month we try and update this database with for ro6870810 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast CancerNCT03292172
Advanced Ovaria...
Triple Negative...
Atezolizumab
RO6870810
18 Years - Hoffmann-La Roche
A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast CancerNCT03292172
Advanced Ovaria...
Triple Negative...
Atezolizumab
RO6870810
18 Years - Hoffmann-La Roche
A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic SyndromeNCT02308761
Acute Myeloid L...
Myelodysplastic...
RO6870810
18 Years - Hoffmann-La Roche
A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6NCT03255096
Diffuse Large B...
High-Grade B-ce...
RO6870810
Venetoclax
Rituximab
18 Years - Hoffmann-La Roche
A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic SyndromeNCT02308761
Acute Myeloid L...
Myelodysplastic...
RO6870810
18 Years - Hoffmann-La Roche
Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple MyelomaNCT03068351
Multiple Myelom...
RO6870810
daratumumab
18 Years - Hoffmann-La Roche
A Two Part Study of RO6870810. Dose-Escalation Study in Participants With Advanced Solid Tumors and Expansion Study in Participants With Selected MalignanciesNCT01987362
Solid Tumors, A...
RO6870810
18 Years - Hoffmann-La Roche
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: